Lucence promotes lung cancer research at ASCO 2022

LabPulse.com staff writers
May 31, 2022
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400

Oncology company Lucence is directing attention to research presentations involving its amplification-based next-generation sequencing (NGS) technology at this week’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

In three separate poster presentations, Lucence will share data showing how a total nucleic acid approach combining circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) in one liquid biopsy test could increase actionable molecular information in lung cancer patients, according to the company.

Latest in Lung Cancer
Lung Cancer Hotspot Social
Roche data release raises hopes TIGIT drugs can improve lung cancer survival
August 25, 2023
Artificial Intelligence Ai Suit Social
Machine learning models, blood biomarkers in research predict future disease risk
June 12, 2023
At-home or Lab-based STI testing/collection
Sponsored
At-home or Lab-based STI testing/collection
September 6, 2023
Lung Cancer2 Social
Biomarker predicts response to chemo-immunotherapy in lung cancer patients
May 15, 2023
Related Stories
2020 01 08 00 29 4037 Colon Cancer 400
Clinical Utility
ASCO presentation highlights clinical utility of ctDNA testing
2021 12 01 16 11 2152 Lab Blood Dropper V2 400
Cancer
GTC to present liquid biopsy testing approach at ASCO 2022
2022 01 10 23 10 0651 Lab Test Tube Dna Blood 400
HBV
Lucence promotes study of LiquidHallmark biopsy assay
At-home or Lab-based STI testing/collection
Sponsor Content
At-home or Lab-based STI testing/collection
More in Lung Cancer
Roche data release raises hopes TIGIT drugs can improve lung cancer survival
Roche's inadvertent release of interim data from its ongoing late-phase clinical trial has raised hopes that its anti-TIGIT immunotherapy may improve the survival rate of lung cancer patients.
August 25, 2023
Lung Cancer Hotspot Social
Machine learning models, blood biomarkers in research predict future disease risk
Researchers found that analyzing genomic information and blood biomarkers is more accurate and cost-effective than analyzing genomic data alone.
June 12, 2023
Artificial Intelligence Ai Suit Social
Biodesix touts cost-saving potential of pulmonary nodule tests
Its analyses estimated cost savings in a hypothetical population of one million patients in a U.S. Medicare or commercial payer setting over a two-year timeline.
May 30, 2023
Lung Cancer2 Social
Biomarker predicts response to chemo-immunotherapy in lung cancer patients
Researchers see a correlation between CX3CR1 expression and outcomes in NSCLC patients treated with chemo-immunotherapy.
May 15, 2023
Lung Cancer2 Social
Thermo Fisher Scientific, Pfizer collaborate to broaden NGS testing in underserved countries
Under the agreement, Thermo Fisher will select local labs for its NGS technology, ensuring they have the infrastructure, trained staff, and quality control measures to meet industry standards to conduct NGS testing for breast and lung cancer.
May 9, 2023
Sequencing Dna Rna Social
Oncocyte prices $13.86M public offering to support test development, commercialization
Oncocyte intends to use the net proceeds from the offering primarily to promote the development and commercialization of VitaGraft, DetermaIO, and DetermaCNI precision diagnostic tests.
April 3, 2023
Lung Cancer2 Social
Micronoma receives FDA breakthrough device designation for liquid biopsy assay to detect lung carcinoma
The company noted that as a result of the designation, it can expect continued guidance and prioritized reviews from the agency of an upcoming clinical trial, part of a process aimed at obtaining a pre-market approval.
January 11, 2023
Lung Cancer2 Social
Argus Research initiates coverage of BioAffinity Technologies at $9 per share
BioAffinity's CyPath Lung lab-developed test uses flow cytometry and machine-learning algorithms to profile the approximately 20 million cells in an average sputum sample in less than 20 minutes.
December 19, 2022
Lung Cancer Social
University of Louisville developing experimental approach for lung cancer breath test
A research group is leveraging measurements of volatile organic compounds and machine learning to develop a test that detects lung cancer.
December 2, 2022
Lung Cancer Hotspot Social
Chest publication suggests potential for MagArray blood test to stratify lung cancer risk
Its Knodule ID test is a multianalyte assay with algorithmic analysis comprising seven protein biomarkers and six clinical factors.
November 21, 2022
Cancer Lung Social
Biofidelity developing assay for single-molecule detection of multiple gene fusions
The firm said its assay analyzes DNA and RNA concurrently from a single patient sample and can return results within two days.
October 18, 2022
Lung Cancer2 Social
Delfi tapped for European lung cancer screening study
The trial will explore how often people should get screened for lung cancer if their initial CT exam is negative; Delfi's liquid biopsy testing will help investigators assess whether study participants could benefit from a screening CT exam. The trial is being conducted via a partnership with the Netherlands Cancer Institute (NKI) and the institute for DiagNostic Accuracy (iDNA). Delfi will work with the first 9,000 study participants enrolled in the trial through the NKI and Gustave Roussy in Villejuif, France, it said.
September 11, 2022
2022 08 08 21 26 6857 Lung Cancer2 400
Page 1 of 7
Next Page